Saniona and Boehringer Ingelheim extend research term with up to two years
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with up to two years.
“The program is currently in the hit-to-lead stage following the successful completion of target validation, library screening and generation of selective hits using Saniona’s ion channel drug discovery platform. We look forward to continuing our partnership with Boehringer Ingelheim scientists as we work together to identify novel ion channel modulators to restore cognition in patients suffering from cognitive impairment associated with schizophrenia”, said Karin Sandager, CSO of Saniona.
Saniona and Boehringer Ingelheim entered the ongoing research collaboration in 2020. The objective is to identify new treatment options for schizophrenia with a new class of therapeutics, which modulates an undisclosed CNS ion channel target. Boehringer Ingelheim has exclusive worldwide rights to research, develop, manufacture, and commercialize therapeutics identified through the collaboration.
Saniona may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.
In addition, Saniona receives research funding during the joint research period. During the first year of the extension period, Saniona expects to receive research funding of around SEK 12.3 million (€1.1 million).
The total research funding under the company’s collaborations with Boehringer Ingelheim and AstronauTx is consequently expected to increase to about SEK 27.3 million (€2.4 million) on annual basis.